Abstract
Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor cells has been implicated in triggering a complex signal cascade that leads to increased tumor proliferation and survival. Cetuximab is a human-murine chimeric monoclonal antibody designed to target EGFR and competitively inhibit dimerization by circulating ligands. By this mechanism, it works to prevent this signal cascade thus hindering tumor proliferation. Cetuximab has been shown in a randomized phase III clinical trial to significantly increase overall survival when it is added to radiation therapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. In this manuscript, the mechanism of cetuximab with its associated patents is reviewed, with its role with chemotherapy and radiation in the management of head and neck cancer along with future directions of this targeted cancer therapy.
Keywords: Cetuximab, squamous cell carcinoma of the head and neck, radiation therapy, concurrent chemotherapy and radiation, epidermal growth factor receptor, targeted therapy
Recent Patents on Anti-Cancer Drug Discovery
Title: Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Volume: 3 Issue: 2
Author(s): Timothy D. Wagner and Gary Y. Yang
Affiliation:
Keywords: Cetuximab, squamous cell carcinoma of the head and neck, radiation therapy, concurrent chemotherapy and radiation, epidermal growth factor receptor, targeted therapy
Abstract: Dimerization of epidermal growth factor receptor (EGFR) on the cell membrane of tumor cells has been implicated in triggering a complex signal cascade that leads to increased tumor proliferation and survival. Cetuximab is a human-murine chimeric monoclonal antibody designed to target EGFR and competitively inhibit dimerization by circulating ligands. By this mechanism, it works to prevent this signal cascade thus hindering tumor proliferation. Cetuximab has been shown in a randomized phase III clinical trial to significantly increase overall survival when it is added to radiation therapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. In this manuscript, the mechanism of cetuximab with its associated patents is reviewed, with its role with chemotherapy and radiation in the management of head and neck cancer along with future directions of this targeted cancer therapy.
Export Options
About this article
Cite this article as:
Wagner D. Timothy and Yang Y. Gary, Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638776
DOI https://dx.doi.org/10.2174/157489208784638776 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Targeting Translation for Treatment of Cancer - A Novel Role for IRES?
Current Cancer Drug Targets Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry From the Sea to Anticancer Therapy
Current Medicinal Chemistry The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine EDITORIAL(Hot Topic Integrated Therapeutic Approaches in the Treatment of Human Cancer)
Anti-Cancer Agents in Medicinal Chemistry Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms
Current Drug Targets Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Applications of Muscle Electroporation Gene Therapy
Current Gene Therapy Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Monoclonal Antibodies in Solid Tumours
Current Clinical Pharmacology The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology Medical Expert Systems
Current Bioinformatics EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews